Shuqun Cheng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/842535/publications.pdf

Version: 2024-02-01

127 papers 4,095 citations

147566 31 h-index 58 g-index

135 all docs

135
docs citations

135 times ranked 4954 citing authors

#	Article	IF	CITATIONS
1	Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis. Hpb, 2022, 24, 547-557.	0.1	3
2	Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients: A Propensity Score Matching Analysis. Annals of Surgical Oncology, 2022, 29, 949-958.	0.7	4
3	ASO Author Reflections: Impact of Bile Duct Tumor Thrombus in Hepatocellular Carcinoma—Does it Influence Staging Systems?. Annals of Surgical Oncology, 2022, 29, 959-959.	0.7	O
4	A novel online calculator to predict recurrence risk in patients with distal cholangiocarcinoma after radical pancreaticoduodenectomy. Journal of Surgical Oncology, 2022, 125, 377-386.	0.8	6
5	Development and validation of an online calculator to predict early recurrence and longâ€term survival in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 1214-1225.	1.4	7
6	Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China. Hpb, 2022, 24, 1063-1073.	0.1	8
7	Active targeted Janus nanoparticles enable anti-angiogenic drug combining chemotherapy agent to prevent postoperative hepatocellular carcinoma recurrence. Biomaterials, 2022, 281, 121362.	5.7	21
8	Step-by-step and orderly lowering of the height of inferior vena cava tumor thrombus is the key to robot-assisted thrombectomy for Mayo III/IV tumor thrombus. BMC Cancer, 2022, 22, 151.	1.1	1
9	AGK regulates the progression to NASH by affecting mitochondria complex I function. Theranostics, 2022, 12, 3237-3250.	4.6	11
10	Image-matching digital macro-slideâ€"a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma. Hepatology International, 2022, 16, 381-395.	1.9	6
11	DCAF13 promotes breast cancer cell proliferation by ubiquitin inhibiting <i>PERP</i> expression. Cancer Science, 2022, 113, 1587-1600.	1.7	16
12	Prognostic Comparison Between Liver Resection and Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Bile Duct Tumor Thrombus: A Propensity-Score Matching Analysis. Frontiers in Oncology, 2022, 12, 835559.	1.3	2
13	Targeting USP9X–AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2022, 14, 101-127.	2.3	17
14	A novel classification in predicting prognosis and guiding postoperative management after RO liver resection for patients with hepatocellular carcinoma and microvascular invasion. European Journal of Surgical Oncology, 2022, 48, 1348-1355.	0.5	11
15	Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory. Frontiers in Oncology, 2022, 12, 839605.	1.3	8
16	Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study. Hpb, 2022, , .	0.1	1
17	Transarterial chemoembolization plus a PDâ€1 inhibitor with or without lenvatinib for intermediateâ€stage hepatocellular carcinoma. Hepatology Research, 2022, 52, 721-729.	1.8	21
18	Robotic versus open pancreaticoduodenectomy for distal cholangiocarcinoma: a multicenter propensity score-matched study. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 8237-8248.	1.3	2

#	Article	IF	CITATIONS
19	Reply to: Letter to the Editor "Association of type 2 diabetes mellitus with incidences of microvascular invasion and survival outcomes in hepatitis B virus-related hepatocellular carcinoma after liver resection: A multicenter study― European Journal of Surgical Oncology, 2022, , .	0.5	O
20	Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages Oâ€"A hepatocellular carcinoma patients associated with or without microvascular invasion: a multicenter, propensity score matching analysis. Hepatology International, 2022, 16, 892-905.	1.9	7
21	Developmental artificial neural network model to evaluate the preoperative safe limit of future liver remnant volume for HCC combined with clinically significant portal hypertension. Future Oncology, 2022, 18, 2683-2694.	1.1	1
22	Robotic pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: A largeâ€scale study. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 942-952.	1.4	3
23	Thrombus-First Surgery for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus. Journal of Gastrointestinal Surgery, 2021, 25, 1973-1979.	0.9	4
24	Compartmentalized evolution of hepatitis B virus contributes differently to the prognosis of hepatocellular carcinoma. Carcinogenesis, 2021, 42, 461-470.	1.3	11
25	Loss of STAT5A promotes glucose metabolism and tumor growth through miRNAâ€23aâ€AKT signaling in hepatocellular carcinoma. Molecular Oncology, 2021, 15, 710-724.	2.1	9
26	A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus. Hepatobiliary Surgery and Nutrition, 2021, 10, 0-0.	0.7	12
27	Typing of biliary tumor thrombus influences the prognoses of patients with hepatocellular carcinoma. Cancer Biology and Medicine, 2021, 18, 808-815.	1.4	3
28	Hepatocellular Carcinoma with Portal Vein Tumor Thrombus versus Hepatocellular Carcinoma with Biliary Tumor Thrombus: Better or Worse Prognoses? [Letter]. Cancer Management and Research, 2021, Volume 13, 987-988.	0.9	0
29	Impact of splenomegaly and splenectomy on prognosis in hepatocellular carcinoma with portal vein tumor thrombus treated with hepatectomy. Annals of Translational Medicine, 2021, 9, 247-247.	0.7	7
30	ASO Author Reflections: Treatment for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus—Anatomic Resection Should Be Recommended. Annals of Surgical Oncology, 2021, 28, 7696-7697.	0.7	0
31	A stable and reliable animal model for hepatocellular carcinoma with portal vein tumor thrombus. Hepatobiliary and Pancreatic Diseases International, 2021, 21, 90-90.	0.6	1
32	A nomogram based on combining systemic and hepatic inflammation markers for predicting microscopic bile duct tumour thrombus in hepatocellular carcinoma. BMC Cancer, 2021, 21, 272.	1.1	1
33	Concurrent bile duct resection versus concomitant thrombectomy for hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis. Annals of Translational Medicine, 2021, 9, 457-457.	0.7	1
34	Nujiangexanthone A Inhibits Hepatocellular Carcinoma Metastasis via Down Regulation of Cofilin 1. Frontiers in Cell and Developmental Biology, 2021, 9, 644716.	1.8	4
35	Long-Term Outcomes of Anatomic Versus Nonanatomic Resection in Hepatocellular Carcinoma Patients with Bile Duct Tumor Thrombus: A Propensity Score Matching Analysis. Annals of Surgical Oncology, 2021, 28, 7686-7695.	0.7	6
36	Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study. Cancer Management and Research, 2021, Volume 13, 3551-3560.	0.9	1

#	Article	IF	CITATIONS
37	NET1 promotes HCC growth and metastasis in vitro and in vivo via activating the Akt signaling pathway. Aging, 2021, 13, 10672-10687.	1.4	5
38	Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China. Hepatology International, 2021, 15, 642-650.	1.9	24
39	AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 650963.	1.3	13
40	PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling. Nature Communications, 2021, 12, 3059.	5.8	18
41	Development and validation of glycolysisâ€related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2021, 25, 5615-5627.	1.6	9
42	Surgical resection for hepatocellular carcinoma with bile duct tumor thrombus. Surgery, 2021, 169, 1424-1426.	1.0	1
43	Association of Preoperative Coagulability With Incidence and Extent of Portal Vein Tumor Thrombus and Survival Outcomes in Hepatocellular Carcinoma After Hepatectomy: A Large-Scale, Multicenter Study. Frontiers in Oncology, 2021, 11, 697073.	1.3	1
44	Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. Oncogene, 2021, 40, 5302-5313.	2.6	11
45	Association of type 2 diabetes mellitus with incidences of microvascular invasion and survival outcomes in hepatitis B virus-related hepatocellular carcinoma after liver resection: A multicenter study. European Journal of Surgical Oncology, 2021, , .	0.5	8
46	Liver resection versus intensity-modulated radiation therapy for treatment of hepatocellular carcinoma with hepatic vein tumor thrombus: a propensity score matching analysis. Hepatobiliary Surgery and Nutrition, 2021, 10, 646-660.	0.7	11
47	ASO Visual Abstract: Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients—A Propensity Score-Matching Analysis. Annals of Surgical Oncology, 2021, 28, 771-771.	0.7	0
48	Prognostic Value of Microvascular Invasion in Eight Existing Staging Systems for Hepatocellular Carcinoma: A Bi-Centeric Retrospective Cohort Study. Frontiers in Oncology, 2021, 11, 726569.	1.3	5
49	The Tumor Suppressor Interferon Regulatory Factor 2 Binding Protein 2 Regulates Hippo Pathway in Liver Cancer by a Feedback Loop in Mice. Hepatology, 2020, 71, 1988-2004.	3.6	22
50	The impact of portal vein tumor thrombus on long-term survival after liver resection for primary hepatic malignancy. Hpb, 2020, 22, 1025-1033.	0.1	8
51	Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer, 2020, 9, 28-40.	4.2	93
52	A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. Hepatobiliary Surgery and Nutrition, 2020, 9, 717-728.	0.7	11
53	A Multidisciplinary Team Approach to the Management of Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Oncologist, 2020, 25, e998.	1.9	3
54	Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways. Nature Cancer, 2020, 1, 735-747.	5.7	31

#	Article	IF	Citations
55	Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4770-4780.	3.3	76
56	A panel of five plasma proteins for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma in individuals at risk. EBioMedicine, 2020, 52, 102638.	2.7	8
57	CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma. Pharmacological Research, 2020, 157, 104800.	3.1	23
58	Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study. Hepatology International, 2020, 14, 754-764.	1.9	29
59	Epithelial Vâ€like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBBâ€PI3Kâ€AKT pathway. Cancer Science, 2020, 111, 1500-1513.	1.7	11
60	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 2020, 9, 682-720.	4.2	427
61	Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex. PLoS Biology, 2020, 18, e3000803.	2.6	29
62	Scinderin suppresses cell proliferation and predicts the poor prognosis of hepatocellular carcinoma. Oncology Letters, 2020, 19, 2011-2020.	0.8	4
63	The effect of bile duct tumor thrombus on the long-term prognosis of hepatocellular carcinoma patients after liver resection: a systematic review and meta-analysis. Annals of Translational Medicine, 2020, 8, 1683-1683.	0.7	3
64	Comparison of different surgical interventions for hepatocellular carcinoma with bile duct tumor thrombus: a systematic review and meta-analysis. Annals of Translational Medicine, 2020, 8, 1567-1567.	0.7	4
65	A serological scoring system to predict lymph node metastasis in patients with hepatocellular carcinoma. Hpb, 2019, 21, 335-344.	0.1	2
66	BMP10 suppresses hepatocellular carcinoma progression via PTPRS–STAT3 axis. Oncogene, 2019, 38, 7281-7293.	2.6	19
67	Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology and Hepatology, 2019, 4, 721-730.	3.7	105
68	Association of Preoperative Hypercoagulability with Poor Prognosis in Hepatocellular Carcinoma Patients with Microvascular Invasion After Liver Resection: A Multicenter Study. Annals of Surgical Oncology, 2019, 26, 4117-4125.	0.7	16
69	Reply. Hepatology, 2019, 70, 1878-1879.	3.6	0
70	ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy. Nature Communications, 2019, 10, 3391.	5.8	75
71	Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: AÂsystematic review and meta-analysis. European Journal of Surgical Oncology, 2019, 45, 2188-2196.	0.5	53
72	Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after RO liver resection: a propensity score matching analysis. Hpb, 2019, 21, 1687-1696.	0.1	57

#	Article	IF	CITATIONS
73	ASO Author Reflections: Preoperative Hypercoagulability Predicts Poor Prognosis in Hepatocellular Carcinoma Patients with Microvascular Invasion After Hepatectomy. Annals of Surgical Oncology, 2019, 26, 806-807.	0.7	2
74	ASO Author Reflections: The Role of Postoperative Adjuvant Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Hepatic Vein Invasion. Annals of Surgical Oncology, 2019, 26, 709-710.	0.7	1
75	MicroRNA‑101 modulates cisplatin chemoresistance in liver cancer cells via the DNA‑PKcs signaling pathway. Oncology Letters, 2019, 18, 3655-3663.	0.8	12
76	In-hospital Mortality after Surgical Resection in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus. Journal of Cancer, 2019, 10, 72-80.	1.2	9
77	Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial. Radiotherapy and Oncology, 2019, 140, 20-25.	0.3	36
78	CHML promotes liver cancer metastasis by facilitating Rab14 recycle. Nature Communications, 2019, 10, 2510.	5.8	32
79	Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. Frontiers in Oncology, 2019, 9, 370.	1.3	42
80	Identification of portal vein tumor thrombus with an independent clonal origin in hepatocellular carcinoma via multi-omics data analysis. Cancer Biology and Medicine, 2019, 16, 147.	1.4	6
81	All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial. Trials, 2019, 20, 245.	0.7	6
82	A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after RO liver resection: A large-scale, multicenter study. European Journal of Surgical Oncology, 2019, 45, 1644-1651.	0.5	29
83	Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis. Hpb, 2019, 21, 935-944.	0.1	53
84	Engineering of Yin Yang-like nanocarriers for varisized guest delivery and synergistic eradication of patient-derived hepatocellular carcinoma. Nanoscale Horizons, 2019, 4, 1046-1055.	4.1	8
85	Liver cancer: WISP3 suppresses hepatocellular carcinoma progression by negative regulation of βâ€catenin/TCF/LEF signalling. Cell Proliferation, 2019, 52, e12583.	2.4	18
86	Postoperative Adjuvant Transarterial Chemoembolization Improves Outcomes of Hepatocellular Carcinoma Associated with Hepatic Vein Invasion: A Propensity Score Matching Analysis. Annals of Surgical Oncology, 2019, 26, 1465-1473.	0.7	38
87	An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After RO Liver Resection: A Large-Scale, Multicenter Study. Oncologist, 2019, 24, e1476-e1488.	1.9	46
88	An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study. Hepatology, 2019, 69, 2076-2090.	3.6	89
89	Thrombocytopenia: A prognostic factor for hepatocellular carcinoma patients with portal vein tumor thrombus after hepatectomy. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1214-1221.	1.4	8
90	Upregulation of Spondin-2 protein expression correlates with poor prognosis in hepatocellular carcinoma. Journal of International Medical Research, 2019, 47, 569-579.	0.4	10

#	Article	IF	CITATIONS
91	Comment on "The Virtual Hepatectomy Changed the Practice of Liver Surgery: More Details, More Significanceâ€. Annals of Surgery, 2019, 270, e32-e33.	2.1	2
92	Liver resection versus transcatheter arterial chemoembolization for the treatment of patients with hepatocellular carcinoma and hepatic vein or inferior vena cava tumor thrombus: A propensity score matching analysis. Hepatology Research, 2019, 49, 441-452.	1.8	13
93	Co-Upregulation of 14-3-3ζ and P-Akt is Associated with Oncogenesis and Recurrence of Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2018, 45, 1097-1107.	1.1	12
94	hPCL3s Promotes Hepatocellular Carcinoma Metastasis by Activating \hat{l}^2 -Catenin Signaling. Cancer Research, 2018, 78, 2536-2549.	0.4	34
95	Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease?. Hepatology, 2018, 68, 786-786.	3.6	5
96	Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis. British Journal of Cancer, 2018, 118, 1337-1348.	2.9	62
97	Hepatocellular carcinoma with hepatic vein invasion should not be considered a contraindication for liver resection. Hepatology, 2018, 67, 804-805.	3.6	6
98	Surveillance for Early-Stage Hepatocellular Carcinoma byÂUltrasound Plus Alpha-Fetoprotein Measurement: More Details, More Significance. Gastroenterology, 2018, 155, 1274-1275.	0.6	3
99	Overexpression of PCK1 Gene Antagonizes Hepatocellular Carcinoma Through the Activation of Gluconeogenesis and Suppression of Glycolysis Pathways. Cellular Physiology and Biochemistry, 2018, 47, 344-355.	1.1	57
100	PRMT1 Promoted HCC Growth and Metastasis In Vitro and In Vivo via Activating the STAT3 Signalling Pathway. Cellular Physiology and Biochemistry, 2018, 47, 1643-1654.	1.1	33
101	FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma. Cancer Medicine, 2018, 7, 2629-2640.	1.3	55
102	Vacuolar Protein Sorting 33B Is a Tumor Suppressor in Hepatocarcinogenesis. Hepatology, 2018, 68, 2239-2253.	3.6	37
103	Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma. BMC Cancer, 2017, 17, 304.	1.1	36
104	Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. BMC Cancer, 2017, 17, 902.	1.1	48
105	Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget, 2017, 8, 8867-8876.	0.8	56
106	The degree of hepatic arterial blood supply of portal vein tumor thrombus in patients with hepatocellular carcinoma and its impact on overall survival after transarterial chemoembolization. Oncotarget, 2017, 8, 79816-79824.	0.8	15
107	Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement. Oncotarget, 2016, 7, 40816-40829.	0.8	38
108	Application of cystoscope in surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. World Journal of Gastroenterology, 2016, 22, 5297.	1.4	1

#	Article	IF	Citations
109	14-3-3Î \P promotes hepatocellular carcinoma venous metastasis by modulating hypoxia-inducible factor-1Î \pm . Oncotarget, 2016, 7, 15854-15867.	0.8	31
110	Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy. Hpb, 2016, 18, 549-556.	0.1	42
111	ICAM-1–Related Noncoding RNA in Cancer Stem Cells Maintains ICAM-1 Expression in Hepatocellular Carcinoma. Clinical Cancer Research, 2016, 22, 2041-2050.	3.2	76
112	Gene copy number variations in the leukocyte genome of hepatocellular carcinoma patients with integrated hepatitis B virus DNA. Oncotarget, 2016, 7, 8006-8018.	0.8	2
113	Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest. Experimental and Therapeutic Medicine, 2015, 9, 1709-1718.	0.8	14
114	Sorafenib enriches epithelial cell adhesion molecule–positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2â€AKT cascade. Hepatology, 2015, 62, 1791-1803.	3.6	54
115	Association between HBV Pre-S mutations and the intracellular HBV DNAs in HBsAg-positive hepatocellular carcinoma in China. Clinical and Experimental Medicine, 2015, 15, 483-491.	1.9	6
116	Ubiquitylation of Autophagy Receptor Optineurin by HACE1 Activates Selective Autophagy for Tumor Suppression. Cancer Cell, 2014, 26, 106-120.	7.7	198
117	The Intracellular HBV DNAs as Novel and Sensitive Biomarkers for the Clinical Diagnosis of Occult HBV Infection in HBeAg Negative Hepatocellular Carcinoma in China. PLoS ONE, 2014, 9, e107162.	1.1	8
118	Experimental study on enhancement of the metastatic potential of portal vein tumor thrombus-originated hepatocellular carcinoma cells using portal vein serum. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 588-95.	0.7	6
119	Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90. Oncology, 2013, 84, 311-318.	0.9	134
120	All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer. Journal of Hepatology, 2013, 59, 1255-1263.	1.8	81
121	TGF-Î ² -miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma. Cancer Cell, 2012, 22, 291-303.	7.7	466
122	MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 389-396.	1.8	146
123	A new classification for hepatocellular carcinoma with portal vein tumor thrombus. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 74-80.	1.4	145
124	Surgical Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Annals of Surgical Oncology, 2010, 17, 2073-2080.	0.7	239
125	Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-κB signaling pathway. Hepatology, 2010, 51, 535-544.	3.6	42
126	Hilar cholangiocarcinoma with synchronous metastases to breast and skeletal muscle: A case report and literature review. Chinese-German Journal of Clinical Oncology, 2006, 5, 216-218.	0.1	6

Shuqun Cheng

#	Article	IF	CITATIONS
127	Expression of the Glypican-3 Gene in $\hat{l}\pm$ -fetoprotein-negative Human Hepatocellular Carcinoma. Chinese-German Journal of Clinical Oncology, 2005, 4, 262-266.	0.1	3